Literature DB >> 26478814

Nitrergic Mechanisms for Management of Recurrent Priapism.

Uzoma A Anele1, Arthur L Burnett1.   

Abstract

INTRODUCTION: Priapism is a condition involving prolonged penile erection unrelated to sexual interest or desire. The ischemic type, including its recurrent variant, is often associated with both physical and psychological complications. As such, management is of critical importance. Ideal therapies for recurrent priapism should address its underlying pathophysiology. AIM: To review the available literature on priapism management approaches particularly related to nitrergic mechanisms.
METHODS: A literature review of the pathophysiology and management of priapism was performed using PubMed. MAIN OUTCOME MEASURE: Publications pertaining to mechanisms of the molecular pathophysiology of priapism.
RESULTS: Nitrergic mechanisms are characterized as major players in the molecular pathophysiology of priapism. PDE5 inhibitors represent an available therapeutic option with demonstrated ability in attenuating these underlying nitrergic derangements. Several additional signaling pathways have been found to play a role in the molecular pathophysiology of priapism and have also been associated with these nitrergic mechanisms.
CONCLUSION: An increasing understanding of the molecular pathophysiology of priapism has led to the discovery of new potential targets. Several mechanism-based therapeutic approaches may become available in the future.

Entities:  

Year:  2015        PMID: 26478814      PMCID: PMC4607075          DOI: 10.1002/smrj.56

Source DB:  PubMed          Journal:  Sex Med Rev        ISSN: 2050-0521


  96 in total

1.  Priapism; reasons for failure of therapy.

Authors:  F HINMAN
Journal:  J Urol       Date:  1960-04       Impact factor: 7.450

Review 2.  Cyclic GMP phosphodiesterase-5: target of sildenafil.

Authors:  J D Corbin; S H Francis
Journal:  J Biol Chem       Date:  1999-05-14       Impact factor: 5.157

3.  Effect of intracavernosal sodium nitroprusside in impotence.

Authors:  F Tarhan; U Kuyumcuoğlu; A Kolsuz; A Ozgül; O Cangüven
Journal:  Urol Int       Date:  1996       Impact factor: 2.089

4.  Daily phosphodiesterase type 5 inhibitor therapy as rescue for recurrent ischemic priapism after failed androgen ablation.

Authors:  Phillip M Pierorazio; Trinity J Bivalacqua; Arthur L Burnett
Journal:  J Androl       Date:  2010-12-02

5.  Priapism in teenage boys following depot testosterone.

Authors:  James F Donaldson; Nikki Davis; Justin H Davies; Roland W Rees; Henrik A Steinbrecher
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

6.  Priapism, its incidence and seasonal distribution in Finland.

Authors:  R V Kulmala; T A Lehtonen; T L Tammela
Journal:  Scand J Urol Nephrol       Date:  1995-03

7.  Mechanisms of venous occlusion during canine penile erection: an anatomic demonstration.

Authors:  G R Fournier; K P Juenemann; T F Lue; E A Tanagho
Journal:  J Urol       Date:  1987-01       Impact factor: 7.450

8.  Opiorphin is a master regulator of the hypoxic response in corporal smooth muscle cells.

Authors:  Shibo Fu; Moses Tarndie Tar; Arnold Melman; Kelvin Paul Davies
Journal:  FASEB J       Date:  2014-05-06       Impact factor: 5.191

9.  Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa.

Authors:  Annamaria Morelli; Sandra Filippi; Rosa Mancina; Michaela Luconi; Linda Vignozzi; Mirca Marini; Claudio Orlando; Gabriella Barbara Vannelli; Antonio Aversa; Alessandro Natali; Gianni Forti; Mauro Giorgi; Emmanuele A Jannini; Fabrizio Ledda; Mario Maggi
Journal:  Endocrinology       Date:  2004-02-05       Impact factor: 4.736

10.  Follow-up of sickle cell disease patients with priapism treated by hydroxyurea.

Authors:  Sara T O Saad; Camila Lajolo; Simone Gilli; José Francisco C Marques Júnior; Carmen S Lima; Fernando F Costa; Valder R Arruda
Journal:  Am J Hematol       Date:  2004-09       Impact factor: 10.047

View more
  3 in total

1.  Erectile function outcomes following surgical treatment of ischemic priapism.

Authors:  Moez Rahoui; Yassine Ouanes; Chaker Kays; Bibi Mokhtar; Kheireddine Mrad Dali; Ahmed Sellami; Sami Ben Rhouma; Yassine Nouira
Journal:  Ann Med Surg (Lond)       Date:  2022-04-29

Review 2.  Advances in the understanding of priapism.

Authors:  Matthew Hudnall; Amanda B Reed-Maldonado; Tom F Lue
Journal:  Transl Androl Urol       Date:  2017-04

3.  Daily tadalafil for the chronic phase of stuttering priapism: a case report.

Authors:  Paolo Massenio; Nicola D'Altilia; Francesca Sanguedolce; Giuseppe Carrieri; Luigi Cormio
Journal:  BMC Urol       Date:  2018-05-31       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.